Largest biotech by earnings
Net income for the latest fiscal year: what was left for shareholders after every cost, interest and tax. A negative figure is a loss.
Gilead Sciences leads the 24 biotech ranked by earnings, at ZAR 146.3B, ahead of Amgen (ZAR 132.6B) and Biogen (ZAR 22.2B). Figures as of 18 Nov 2026, 15:06 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Gilead SciencesZAR 146.3B
- Median
- -ZAR 1.2B
- Combined market value
- ZAR 14.61T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Earnings ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | ZAR 146.3B | ZAR 3.62T | ZAR 2,919.40 | 0.28% down | 33% up | ||
| 2 | AmgenAMGN · Health Care | ZAR 132.6B | ZAR 4.21T | ZAR 7,780.04 | 1.19% down | 34% up | ||
| 3 | BiogenBIIB · Health Care | ZAR 22.2B | ZAR 638B | ZAR 4,315.75 | 0.08% up | 49% up | ||
| 4 | argenxARGX · Health Care | ZAR 22.2B | ZAR 1.04T | ZAR 16,558.54 | 1.64% up | 4% up | ||
| 5 | ExelixisEXEL · Health Care | ZAR 13.5B | ZAR 290.4B | ZAR 1,190.01 | 1.04% up | 63% up | ||
| 6 | Neurocrine BiosciencesNBIX · Health Care | ZAR 8.2B | ZAR 285.4B | ZAR 2,820.02 | 1.15% down | 20% up | ||
| 7 | QiagenQGEN · Health Care | ZAR 7.3B | ZAR 176.5B | ZAR 854.64 | 0.09% down | 12% up | ||
| 8 | Halozyme TherapeuticsHALO · Health Care | ZAR 5.4B | ZAR 190.5B | ZAR 1,670.76 | 1.25% up | 37% up | ||
| 9 | Krystal BiotechKRYS · Health Care | ZAR 3.5B | ZAR 157.5B | ZAR 5,314.39 | 3.53% up | 46% up | ||
| 10 | Bio-TechneTECH · Health Care | ZAR 3.1B | ZAR 196.4B | ZAR 1,250.53 | 0.14% up | 26% up | ||
| 11 | RepligenRGEN · Health Care | ZAR 840.7M | ZAR 190.3B | ZAR 2,977.18 | 6.76% up | 5% up | ||
| 12 | Adaptive BiotechnologiesADPT · Health Care | -ZAR 1B | ZAR 80.8B | ZAR 499.15 | 1.90% up | 88% up | ||
| 13 | Twist BioscienceTWST · Health Care | -ZAR 1.3B | ZAR 138.7B | ZAR 2,033.90 | 5.62% up | 340% up | ||
| 14 | CG OncologyCGON · Health Care | -ZAR 2.8B | ZAR 118.9B | ZAR 1,331.61 | 1.89% down | 85% up | ||
| 15 | Kodiak SciencesKOD · Health Care | -ZAR 4B | ZAR 111.3B | ZAR 1,702.23 | 2.27% up | 396% up | ||
| 16 | Kymera TherapeuticsKYMR · Health Care | -ZAR 5.4B | ZAR 181.5B | ZAR 2,125.98 | 1.75% up | 87% up | ||
| 17 | ImmunityBioIBRX · Health Care | -ZAR 6B | ZAR 119.5B | ZAR 112.36 | 4.39% up | 193% up | ||
| 18 | Scholar Rock HoldingSRRK · Health Care | -ZAR 6.5B | ZAR 100.2B | ZAR 821.02 | 5.92% up | 14% up | ||
| 19 | ImmunovantIMVT · Health Care | -ZAR 8.7B | ZAR 120.1B | ZAR 580.13 | 1.60% up | 43% up | ||
| 20 | CRISPR TherapeuticsCRSP · Health Care | -ZAR 10B | ZAR 70.2B | ZAR 724.22 | 4.91% up | 21% down | ||
| 21 | VaxcytePCVX · Health Care | -ZAR 13.2B | ZAR 161.4B | ZAR 1,019.62 | 0.17% down | 22% up | ||
| 22 | Revolution MedicinesRVMD · Health Care | -ZAR 19.5B | ZAR 602.6B | ZAR 2,786.15 | 0.40% down | 131% up | ||
| 23 | BioNTechBNTX · Health Care | -ZAR 21.7B | ZAR 362.2B | ZAR 1,460.99 | 0.13% up | 16% down | ||
| 24 | ModernaMRNA · Health Care | -ZAR 48.5B | ZAR 1.44T | ZAR 3,568.92 | 0.37% up | 755% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Earnings is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 17.1942 ZAR).
Questions and answers
Which biotech rank first by earnings?
Gilead Sciences (ZAR 146.3B), Amgen (ZAR 132.6B) and Biogen (ZAR 22.2B) are the top three of the 24 biotech ranked by earnings as of 18 Nov 2026, 15:06 UTC.
How many biotech are in this ranking?
24 are ranked by earnings.
What are these biotech worth together?
The 24 biotech ranked by earnings have a combined market value of ZAR 14.61T as of 18 Nov 2026, 15:06 UTC.
What does ranking by earnings measure?
Net income for the latest fiscal year: what was left for shareholders after every cost, interest and tax. A negative figure is a loss.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest biotech by earnings”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=earnings
Underlying data: Yahoo Finance; SEC EDGAR.